Literature DB >> 33791385

Observations on the Efficacy of Two Methods for the Treatment of Upper Eyelid Retraction in Thyroid-Associated Ophthalmopathy.

Dongping Li1,2,3, Fengyuan Sun2,3.   

Abstract

OBJECTIVE: To observe the clinical efficacy of periocular injection of triamcinolone acetonide (TA) and subpalpebral injection of botulinum toxin type A (BTXA) for the treatment of thyroid-associated ophthalmopathy (TAO) with mild unilateral upper eyelid retraction.
METHOD: This was a prospective randomized controlled study. A total of 68 cases of stable thyroid-associated ophthalmopathy with mild upper eyelid retraction were collected at Hankou Aier Eye Hospital from Jan. 2015 to Dec. 2018 and randomly divided into two groups. Group A contained 33 patients who were administered TA by periocular injection once every 3 weeks for a total of 3 times. Group B contained 35 patients who were given a single subpalpebral administration of BTXA. The efficacy in the two groups was observed.
RESULTS: Compared with the two groups, the effective rate in both groups was 100% at 1 week and 1 month after treatment. The effective rate of Group A remained 100% at 3 months after treatment, and that of Group B decreased to 88.6%. At 1 week after treatment, the degree of correction in Group B was greater than that in Group A (p < 0.001). At 1 month after treatment, it was not significantly different between the two groups (p > >>0.05). At 3 months after treatment, it was less in Group B than in Group A (p < 0.001). In Group A, there was one case of transient amaurosis, two cases of periorbital hemorrhage and swelling, and one mild case of sunken eyes. In Group B, four cases experienced recurrence after 3 months.
CONCLUSION: Periocular injection of TA and subpalpebral injection of BTXA offer definite therapeutic efficacy for mild upper eyelid retraction associated with thyroid disease. The former has a long treatment period, large procedural risks, and stable efficacy. The latter is a simple procedure with a short treatment period but can easily recur.
Copyright © 2021 Dongping Li and Fengyuan Sun.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33791385      PMCID: PMC7997737          DOI: 10.1155/2021/9514279

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  17 in total

1.  Peri-levator palpebrae superioris triamcinolone injection for the treatment of thyroid eye disease-associated upper eyelid retraction.

Authors:  Zachary P Joos; Timothy J Sullivan
Journal:  Clin Exp Ophthalmol       Date:  2017-03-28       Impact factor: 4.207

2.  [Management of upper eyelid retraction associated with dysthyroid orbitopathy during the acute inflammatory phase with botulinum toxin type A].

Authors:  A Nava Castañeda; J L Tovilla Canales; L Garnica Hayashi; A Velasco Y Levy
Journal:  J Fr Ophtalmol       Date:  2017-03-21       Impact factor: 0.818

3.  Course of upper eyelid retraction in thyroid eye disease.

Authors:  Dong Cheol Lee; Stephanie M Young; Yoon-Duck Kim; Kyung In Woo
Journal:  Br J Ophthalmol       Date:  2019-05-11       Impact factor: 4.638

4.  Thyroid eye disease presenting with superior rectus/levator complex enlargement.

Authors:  Yao Wang; Pradeep Mettu; Talmage Broadbent; Phillip Radke; Kevin Firl; J Banks Shepherd; Steven M Couch; Angeline Nguyen; Amanda D Henderson; Timothy McCulley; Collin M McClelland; Ali Mokhtarzadeh; Michael S Lee; James A Garrity; Andrew R Harrison
Journal:  Orbit       Date:  2019-05-06

5.  Long-term effect of triamcinolone acetonide in the treatment of upper lid retraction with thyroid associated ophthalmopathy.

Authors:  Dong-Dong Xu; Yu Chen; Hai-Yan Xu; Hui Li; Zhu-Hua Zhang; Yu-Hua Liu
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

6.  Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections.

Authors:  Sung Jun Lee; Tyler Hyung Taek Rim; Sun Young Jang; Chan Yun Kim; Dong Yeob Shin; Eun Jig Lee; Sang Yeul Lee; Jin Sook Yoon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-09-12       Impact factor: 3.117

7.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02

8.  A Promising Modified Procedure for Upper Eyelid Retraction-Associated Graves' Ophthalmopathy: Transconjunctival Lateral Levator Aponeurectomy.

Authors:  Fatima Khatavi; Kobra Nasrollahi; Alireza Zandi; Maryam Panahi; Mahshid Mortazavi; Mohsen Pourazizi; Behzad Ranjbar-Omidi
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2017

9.  Clinical efficacy of transcutaneous triamcinolone acetonide injection for upper eyelid retraction and swelling in patients with thyroid eye disease.

Authors:  Ai Kozaki; Hiroshi Nakamura; Toshu Inoue
Journal:  Int Med Case Rep J       Date:  2018-11-09

Review 10.  Intraorbital Steroid Injection for Active Thyroid Ophthalmopathy.

Authors:  Abbas Bagheri; Mohammad Abbaszadeh; Shahin Yazdani
Journal:  J Ophthalmic Vis Res       Date:  2020-02-02
View more
  2 in total

1.  Risk factors for development of superior limbic keratoconjunctivitis in thyroid eye disease in Japanese.

Authors:  Yasuhiro Takahashi; Aric Vaidya; Hirohiko Kakizaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-09-09       Impact factor: 3.535

2.  Detection and Correlation Analysis of Serum Uric Acid in Patients with Thyroid-Associated Ophthalmopathy.

Authors:  Jingbo Zhou; Xu Yu; Yan Lou; Jinjing Bao; Yuequan Xia; Lin Zhu
Journal:  Comput Math Methods Med       Date:  2022-09-27       Impact factor: 2.809

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.